When Sarah told her elderly mother about what she had found, she was horrified to hear that James had also been sexually ...

The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The appointment of a seasoned pharmaceutical executive, George Tidmarsh, to run the FDA’s drug center underscores the ...

Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday.

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

Most Oncologic Drugs Advisory Committee members took issue with the lack of dosing optimization and the lack of US patient ...

The agreement allows manufacturers to develop, manufacture and supply generic long-acting injectable cabotegravir for ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...

US FDA approves GSK’s Shingrix in a prefilled syringe presentation for prevention of shingles: London, UK Friday, July 18, 2025, 09:00 Hrs [IST] GSK plc announced that the US Fo ...